pharmaphorum December 16, 2025
San Francisco startup Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B that will be used to build its computer-aided design (CAD) suite for drug molecules.
Chai – which is backed by artificial intelligence group OpenAI – was founded last year with a mission to “turn biology from a scientific discipline into an engineering practice.”
Since then, it has launched a second iteration of its AI-powered discovery engine, Chai-2, and has advanced from designing ‘minibinders’ based on antibody fragments, through simple, truncated antibody sequences, to full-length monoclonal antibodies like those used in commercial therapies.
In a recent update, the company said its full-length antibodies are maintaining the...
Today's Sponsors
Today's Sponsor